Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Cancer Immunology, Immunotherapy : CII|February 15, 2012
Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapyNicolò Rigamonti, Matteo BelloneCell Reports|September 3, 2013
A role for angiopoietin-2 in organ-specific metastasisNicolò Rigamonti, Michele De PalmaBMC Immunology|January 13, 2009
Modulators of arginine metabolism support cancer immunosurveillanceGiusy Capuano, Nicolò Rigamonti, Matteo Grioni, et al.Cell Reports|August 5, 2014
Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockadeNicolò Rigamonti, Ece Kadioglu, Ioanna Keklikoglou, et al.New Biotechnology|June 26, 2009
Affibody-mediated retention of the epidermal growth factor receptor in the secretory compartments leads to inhibition of phosphorylation in the kinase domainErik Vernet, Emma Lundberg, Mikaela Friedman, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2011
Modulators of arginine metabolism do not impact on peripheral T-cell tolerance and disease progression in a model of spontaneous prostate cancerNicolò Rigamonti, Giusy Capuano, Alessia Ricupito, et al.Science Translational Medicine|April 14, 2017
Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockadeMartina Schmittnaegel, Nicolò Rigamonti, Ece Kadioglu, et al.Cancer Immunology Research|March 23, 2022
A Multispecific Anti-CD40 DARPin Construct Induces Tumor-Selective CD40 Activation and Tumor RegressionNicolò Rigamonti, Niina Veitonmäki, Clara Domke, et al.Proceedings of the National Academy of Sciences of the United States of America|January 1, 2020
Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapyAbhishek S Kashyap, Martina Schmittnaegel, Nicolò Rigamonti, et al.Pageof 1